In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor | Zendy

Alain Bonnefoy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitor

Author(s) -

Alain Bonnefoy

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh358

Subject(s) - ceftazidime , clavulanic acid , klebsiella pneumoniae , citrobacter freundii , citrobacter , microbiology and biotechnology , sulbactam , proteus mirabilis , enterobacter , enterobacteriaceae , beta lactamase inhibitors , enterobacter cloacae , tazobactam , beta lactamase , escherichia coli , chemistry , biology , bacteria , amoxicillin , imipenem , biochemistry , antibiotics , antibiotic resistance , pseudomonas aeruginosa , gene , genetics

Production of beta-lactamases is the main mechanism of beta-lactam resistance in Gram-negative bacteria. Despite the current use of clavulanic acid, sulbactam and tazobactam, the prevalence of class A and class C enzymes is increasing worldwide, demanding new beta-lactamase inhibitors. Here we report the antimicrobial properties of AVE1330A, a representative of a novel class of bridged bicyclico[3.2.1]diazabicyclo-octanones in combination with ceftazidime.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research